Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Locally Advanced Colorectal Cancer 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Gastric Adenocarcinoma 1Colorectal Cancer Metastatic 1Breast Neoplasms 1Advanced Gastric Cancer 1

Interventions

apatinib 3sintilimab 2Taxes 2Paclitaxel 2Oxaliplatin 2Hyperthermic Intraperitoneal Chemotherapy 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1XELOX 1Tegafur 1Tadalafil 1SHR-1701 1S 1 (combination) 1Platinum 1Magnetic Resonance Spectroscopy 1Injections 1Gastrectomy 1Drug Therapy 1Drug Evaluation 1Docetaxel 1Cytoreduction Surgical Procedures 1Cisplatin 1Capecitabine 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastric Adenocarcinoma × SHR-1701 × Clear all
NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡